Morning Read: Novartis buys up rights to GSK’s MS drug for up to $1B, anthrax vaccine developer Pfenex wins $143.5M contract
Novartis has acquired the remaining rights to GlaxoSmithKline's multiple sclerosis drug Ofatumumab for up to $1 billion. Pfenex, a biotech working on an anthrax vaccine, has won a federal contract worth up to $143.5 million.